Sleep-Glymphatic-Neuroinflammation Pathway Study

1 Background and Rationale

The glymphatic system—the brain’s waste clearance mechanism that is maximally active during sleep—may play a critical role in neuroinflammation control. Poor sleep in ME/CFS could impair glymphatic clearance of neuroinflammatory mediators, perpetuating microglial activation and progressive symptom deterioration. Conversely, treating underlying sleep disorders might interrupt this pathway and slow disease progression. This study tests whether interventions targeting sleep disorders in ME/CFS patients with documented sleep pathology produce measurable reductions in neuroinflammation and slowing of PEM progression.

2 Study Design

2.1 Design Overview

Randomized, prospective study of ME/CFS patients with documented sleep disorders, comparing immediate treatment to delayed (6-month wait-list control) treatment.

2.2 Participants

n=60 ME/CFS patients (ages 18–60) with documented sleep disorders
Sleep disorder documentation via home sleep apnea testing: OSA (AHI \(\geq\) 5 events/hour) or other sleep pathology (insomnia with documented sleep fragmentation, periodic breathing, etc.)
Mild to moderate severity (Bell scale 40–75)
No prior treatment with CPAP, BiPAP, or formal sleep disorder management
Willing to be randomized to immediate vs. delayed treatment

2.3 Randomization

1:1 randomization to:

Immediate treatment (n=30): Sleep disorder management initiated at baseline
Delayed treatment (n=30): Sleep management begins at 6-month mark (wait-list control) Stratification by sleep disorder type (OSA vs. other).

3 Interventions

3.1 Immediate Treatment Arm

OSA patients (CPAP/BiPAP):

Polysomnography or split-night study to determine therapeutic pressure
CPAP or BiPAP initiation with titration protocol
Mask fitting and desensitization
Monthly adherence monitoring for first 3 months, then quarterly
Target: \(\geq\) 4 hours per night use Insomnia or fragmentation:
Sleep restriction therapy with gradual sleep window expansion
Cognitive-behavioral therapy for insomnia (CBT-I) protocol
Pharmacological support: Trazodone or mirtazapine as needed
Weekly coaching sessions for first 4 weeks

3.2 Delayed Treatment Arm

Standard sleep hygiene education only for first 6 months; treatment as above begins at month 6.

4 Measures

4.1 Sleep Assessment (baseline, 6 months, 12 months)

Home sleep apnea testing or portable sleep monitoring
Sleep diary (7-day baseline, 7-day at each timepoint)
Actigraphy (7-day continuous at each timepoint)
Pittsburgh Sleep Quality Index (PSQI)

4.2 Neuroinflammation Markers (baseline, 6 months, 12 months)

CSF sampling (optional lumbar puncture subset, n=20 per arm): TNF-\(\alpha\), IL-6, IL-1\(\beta\), MCP-1, neopterin
Serum inflammatory markers: High-sensitivity CRP, IL-6, TNF-\(\alpha\), IL-1\(\beta\)
TSPO-PET imaging (subset, n=15 per arm): microglial activation assessment

4.3 Clinical Outcome Measures (baseline, 6 months, 12 months)

PEM crash diary (continuous): Frequency, severity, recovery duration
Bell Disability Scale
Cognitive function (Montreal Cognitive Assessment)
Autonomic function (NASA Lean Test, HRV)
DSQ-PEM

5 Outcomes

5.1 Primary Outcomes

Change in inflammatory marker trajectory (serum IL-6) from baseline to 12 months: Immediate vs. delayed arm
PEM threshold stability: Rate of change in PEM severity over 12 months in treated vs. untreated groups

5.2 Secondary Outcomes

Individual inflammatory markers (TNF-\(\alpha\), IL-1\(\beta\), CRP)
CSF markers in subset (if available)
TSPO-PET signal change in imaging subset
Bell Disability Scale change baseline to 12 months
Cognitive function improvement
PEM crash frequency change

5.3 Tertiary Outcomes

Sleep quality improvement and correlation with inflammatory markers
CPAP/BiPAP adherence as moderator of treatment effect
Slow-wave sleep percentage (from polysomnography in subset) and correlation with inflammatory markers

6 Analysis Plan

Primary analysis: Linear mixed-effects model comparing serum IL-6 trajectory over 12 months between arms
Secondary outcomes: ANCOVA for Bell scale and other clinical outcomes at 12 months, adjusted for baseline values
Mediation analysis: Does change in sleep quality mediate the relationship between treatment arm and inflammation?
Adherence analysis: Among immediate arm, does CPAP adherence predict inflammatory marker improvements?

7 Sample Size Justification

With n=30 per arm and 3 measurement timepoints:

80% power to detect 30% difference in IL-6 slope between arms (assuming SD=0.8 in log IL-6) at \(\alpha\)=0.05
Based on preliminary data: treated sleep apnea showing 25–35% reduction in inflammatory markers in healthy controls

8 Expected Outcomes and Implications

If sleep treatment reduces neuroinflammation and slows PEM progression:

Establishes sleep as critical disease-modifying factor
Validates screening and treating sleep disorders as standard ME/CFS care
Identifies glymphatic function as therapeutic target
May support clinical guidelines for aggressive sleep disorder management If sleep treatment shows minimal effect:
Suggests neuroinflammation maintenance is not primarily glymphatic-dependent
Indicates other mechanisms of microglial activation are primary
Redirects focus toward direct microglial targeting (LDN, other agents)

Hypothesis: Metabolic-Immune Crosstalk in LDN Response

LDA-induced metabolic changes (glucose intolerance, insulin resistance) amplify neuroinflammation and create a therapeutic ceiling that limits cognitive benefit over time. Concurrent metformin administration in patients developing prediabetes will preserve LDN efficacy and enhance cognitive outcomes compared to LDN monotherapy. HbA1c improvements correlate with neuroinflammatory marker reduction (MCMC Research 2024).

References

MCMC Research. 2024. “Neurometabolic Modelling of PEM and Central Sensitisation.” 2024. https://www.mcmc-research.com/post/neurometabolic-modelling-of-pem-and-central-sensitisation.